Biotech firm Idenix Pharmaceuticals (NASDAQ: IDIX ) announced Monday that it will not continue developing two of its pipeline drugs: hepatitis C therapy IDX184, which was in phase 2B clinical trial, and another HCV nucleotide polymerase inhibitor, IDX19368.
The FDA put IDX184 on hold in August of last year -- and placed IDX 19368 on clinical hold -- after poor results from a phase 2 trial from competitor Brystol-Myers Squibb's BMS-986094, which encountered "cardiac adverse events," according to Idenix's release. Idenix President and CEO Ron Renaud commented on the company's direction following the decision, saying in the release that it would continue to "maintain our strong presence in developing nucleotide polymerase inhibitors for HCV based on our broad discovery platform."
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Be the first one to comment on this article.